Does INIPARIB Cause Malignant neoplasm progression? 15 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Malignant neoplasm progression have been filed in association with INIPARIB. This represents 41.7% of all adverse event reports for INIPARIB.
15
Reports of Malignant neoplasm progression with INIPARIB
41.7%
of all INIPARIB reports
0
Deaths
15
Hospitalizations
How Dangerous Is Malignant neoplasm progression From INIPARIB?
Of the 15 reports, 15 (100.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for INIPARIB. However, 15 reports have been filed with the FAERS database.
What Other Side Effects Does INIPARIB Cause?
Anaemia (16)
Thrombocytopenia (16)
Disease progression (10)
Invasive ductal breast carcinoma (10)
Metastases to bone marrow (10)
Product use in unapproved indication (10)
Bone marrow infiltration (6)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)